Acute Ischemic Stroke - Pipeline Review, H2 2011
Global Markets Direct’s, 'Acute Ischemic Stroke - Pipeline Review, H2 2011', provides an overview of the Acute Ischemic Stroke therapeutic pipeline. This report provides information on the therapeutic development for Acute Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke. 'Acute Ischemic Stroke - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Acute Ischemic Stroke.
- A review of the Acute Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Ischemic Stroke pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke.
- Identify emerging players with potentially stro
Acute Ischemic Stroke – Pipeline Review, H2 2011 Acute Ischemic Stroke - Pipeline Review, H2 2011 Reference Code: GMDHC1335IDB Publication Date: September 2011 Acute Ischemic Stroke – Pipeline Review, H2 2011 GMDHC1335IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Acute Ischemic Stroke – Pipeline Review, H2 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Acute Ischemic Stroke Overview 11 Therapeutics Development 12 An Overview of Pipeline Products for Acute Ischemic Stroke 12 Acute Ischemic Stroke Therapeutics under Development by Companies 14 Acute Ischemic Stroke Therapeutics under Investigation by Universities/Institutes 16 Late Stage Products 19 Comparative Analysis 19 Mid Clinical Stage Products 20 Comparative Analysis 20 Early Clinical Stage Products 21 Comparative Analysis 21 Discovery and Pre-Clinical Stage Products 22 Comparative Analysis 22 Acute Ischemic Stroke Therapeutics - Products under Development by Companies 23 Acute Ischemic Stroke Therapeutics - Products under Investigation by Universities/Institutes 25 Companies Involved in Acute Ischemic Stroke Therapeutics Development 27 Sanofi-Aventis 27 Eli Lilly and Company 27 Aldagen, Inc. 28 Henry Ford Health System 28 H Lundbeck A/S 29 Mitsubishi Tanabe Pharma Corporation 29 Pfizer Inc. 30 Celgene Corporation 30 Vernalis plc 31 RegeneRx Biopharmaceuticals, Inc. 31 ReNeuron Group plc 32 SYGNIS Pharma AG 32 Torrent Pharmaceuticals Limited 33 ThromboGenics NV 33 D-Pharm Ltd. 34 BioMAS Ltd. 34 Ferrer Internacional S.A. 35 Stemedica Cell Technologies, Inc. 35 M's Science Corporation 36 Thrombotech Technologies, Ltd. 36 Gaia BioPharma Limited 36 Acute Ischemic Stroke - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Acute Ischemic Stroke – Pipeline Review, H2 2011 GMDHC1335IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Acute Ischemic Stroke – Pipeline Review, H2 2011 Drug Profiles 43 Desmoteplase - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 MCI-186 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ILS-920 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 PDA001 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 MP-124 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Citicoline - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Ocriplasmin - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 DP-b99 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 GAI-122 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AX200 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 RGN-352 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Radicut - Drug Profile 56 Product Description 56 Mechanism of Action 56 Acute Ischemic Stroke – Pipeline Review, H2 2011 GMDHC1335IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3) Acute Ischemic Stroke – Pipeline Review, H2 2011 R&D Progress 56 SA4503 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 V10153 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Minocycline - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Activase + Integrilin - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Aricept - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 AS101 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NA-1 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Effient - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Deferoxamine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Integrillin + Aspirin + Innohep - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Recombinant Tissue Plasminogen Activator - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Argatroban + Alteplase - Drug Profile 70 Product Description 70 Mechanism of Action 70 Acute Ischemic Stroke – Pipeline Review, H2 2011 GMDHC1335IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4) Acute Ischemic Stroke – Pipeline Review, H2 2011 R&D Progress 70 Human Serum Albumin Infusion - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Aricept - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Clopidogrel - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Xiaoshuanchangrong - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Dapsone - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Propranolol - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Insulin - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Magnesium Sulfate - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Filgrastim - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 GM602 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 SAR 104772 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 CTX0E03 - Drug Profile 82 Product Description 82 Mechanism of Action 82 Acute Ischemic Stroke – Pipeline Review, H2 2011 GMDHC1335IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(5) Acute Ischemic Stroke – Pipeline Review, H2 2011 R&D Progress 82 ALD-401 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Avonex - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 WE-Thrombin - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Warfarin - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Aspirin - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Noscapine - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Activase - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Allogeneic Mesenchymal Bone Marrow Cells - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Thymosin beta 4 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 THR-18 + tPA - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 TRC-6XXX - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Acute Ischemic Stroke Therapeutics – Drug Profile Updates 94 Acute Ischemic Stroke Therapeutics - Discontinued Products 100 Acute Ischemic Stroke - Featured News 101 Acute Ischemic Stroke – Pipeline Review, H2 2011 GMDHC1335IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(6) Acute Ischemic Stroke – Pipeline Review, H2 2011 Aug 24, 2011: D-Pha
Pages to are hidden for
"Acute Ischemic Stroke Pipeline Review H2 2011"Please download to view full document